An early study of 23 R/R cHL patients, demonstrated objective response rate (ORR) of 87% and complete response rate (CR) of 17% to the PD-1 monoclonal antibody (mAb) nivolumab [76]. The gene discussed is PDCD1; the disease is classic Hodgkin lymphoma.